Long-term safety and efficacy of ponatinib in intolerant chronic myeloid leukemia: subanalysis of the observational study of Iclusig® (ponatinib) treatment in patients with chronic myeloid leukemia in Italy

Puntos clave

• The aim is to evaluate the long-term safety and efficacy of ponatinib in patients with chronic myeloid leukemia who are intolerant to other treatments.
• Subanalysis of an observational study on ponatinib treatment
• Evaluation of patients with chronic myeloid leukemia
• Focus on long-term effects and patient tolerability.
• Significant improvement in patient outcomes over the long term
• Management of intolerance effectively addressed with ponatinib therapy
• Overall safety profile deemed acceptable among treated patients.